United Therapeutics director sells 200 shares

UNITED THERAPEUTICS Corp director Judy D. Olian reported an open-market sale of 200 shares of common stock at $530 per share.

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp director Judy D. Olian reported an open-market sale of 200 shares of common stock at $530 per share. The transaction occurred on March 23, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan entered into on November 4, 2025. After this sale, she directly holds 4,245 shares of UNITED THERAPEUTICS common stock.

Insights

Equity ownership and insider-trading analyst

Small, pre-planned director sale with most holdings retained.

Director Judy D. Olian executed an open-market sale of 200 shares of UNITED THERAPEUTICS common stock at $530 per share. This reduces her directly held position to 4,245 shares, so only a limited portion of her stake was sold.

The filing notes the trade was carried out under a pre-arranged Rule 10b5-1 plan entered on November 4, 2025. Such plans schedule trades in advance, which typically makes the timing less indicative of the insider’s current view of the stock.

There are no derivative positions reported in this filing, suggesting the focus is solely on common stock ownership. Subsequent company filings may provide further context if additional 10b5-1 plan sales occur or if her overall equity stake changes materially.

Insider Trade Summary 10b5-1

Net Seller: 200 shares

Net Sell 1 txn

Insider Olian Judy D.

Role Director

Sold 200 shs ($106K)

Type	Security	Shares	Price	Value
Sale	Common Stock	200	$530.00	$106K

Holdings After Transaction: Common Stock — 4,245 shares (Direct)

Footnotes (1)

1. F1. This is a sale of common stock pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 4, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did UNITED THERAPEUTICS (UTHR) report for Judy D. Olian?

Judy D. Olian reported selling 200 shares of UNITED THERAPEUTICS common stock. The Form 4 shows an open-market sale at $530 per share, leaving her with 4,245 directly held shares after the transaction disclosed for March 23, 2026.

At what price did Judy D. Olian sell UNITED THERAPEUTICS (UTHR) shares?

She sold the shares at $530 per share. The Form 4 lists an open-market sale of 200 shares of UNITED THERAPEUTICS common stock at that price on March 23, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

How many UNITED THERAPEUTICS (UTHR) shares does Judy D. Olian hold after this sale?

After the reported sale, she directly holds 4,245 shares. The Form 4’s post-transaction ownership field shows 4,245 shares of common stock remaining in her direct ownership following the 200-share open-market sale on March 23, 2026.

Was Judy D. Olian’s UNITED THERAPEUTICS (UTHR) stock sale part of a 10b5-1 plan?

Yes. The sale was made under a pre-arranged Rule 10b5-1 plan. A footnote explains the 200-share sale of common stock occurred pursuant to a trading plan that she entered into on November 4, 2025, indicating the transaction was scheduled in advance.

What type of insider transaction did UNITED THERAPEUTICS (UTHR) disclose for Judy D. Olian?

The company disclosed an open-market sale of common stock. The Form 4 identifies the transaction code as “S”, described as a sale in an open market or private transaction, covering 200 shares of UNITED THERAPEUTICS common stock at $530 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/24/2026 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Olian Judy D.

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MARYLAND 20910

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/23/2026		S(1)		200	D	$530	4,245	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This is a sale of common stock pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 4, 2025.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)